
Eric Dein ericdeinmd
10 months ago
Rheumatic diseases are highly affected by environmental impacts
Appreciate the ACR for creating a Climate Change Task Force to proactively and reactively respond to the issues this creates for rheumatologist
@ACRheum @dddesir
#ACR24 @RheumNow https://t.co/h4jCMa9Fyg


Eric Dein ericdeinmd
10 months ago
CV risk after gout attack
1.75x increase risk of acute CV risk in first 30 days after gout flare (significant) possibly up to 120 days (didn’t reach significance)
@RheumNow
#ACR24 year in review Pillinger https://t.co/a2zS8mIw3L


sheila RHEUMarampa
10 months ago
Year in review: Can #gout flares increase CV risk?
Cipoletta et al - pts with gout may be at inc risk of CV events for at least 30-120 days after flares.
Emphasize CV risk mgt in all patients w/ gout.
@RheumNow #ACR24 https://t.co/p1aXVgqkuR


Eric Dein ericdeinmd
10 months ago
Knee OA
Krill oil - No benefit in randomized PBO control study
MTX (25 mg) for pain - modest diff in pain (numerical, not WOMAC), lost by 12 mo
STEP-9: GLP1 agonist for BMI>30 w knee OA. 60% better than PBO. Wt or other benefits?
@RheumNow
Michael Pillinger
#ACR24 year in review https://t.co/dMw4T0tWLX


sheila RHEUMarampa
10 months ago
Year in review:
Semaglutide reduced knee pain over 68 weeks in patients with high BMI and moderate knee #osteoarthritis pain
But mechanism of knee pain improvement not yet known if due to wgt loss or other mechanisms.
@Rheumnow #ACR24 @rheumarhyme @theactiverheum https://t.co/PkrcIMbgPl


Brian Jaros, MD Dr_Brian_MD
10 months ago
Abatacept for GPA?
Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA
Continued need for tx options in non-severe relapsing dz
@RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7


Dr. John Cush RheumNow
10 months ago
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and
ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.

Antoni Chan MD (Prof) synovialjoints
10 months ago
Diagnostic work up for sarcoidosis. Think of CVID as an important differential @RheumNow #ACR2024 #sarcoidosis https://t.co/DvJzkN3ZjY


Adela Castro AdelaCastro222
10 months ago
RA pearls from #ACR24 review course:
1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi.
2. Multimorbidity=Poor outcomes, High risk for mortality.
3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg


Eric Dein ericdeinmd
10 months ago
Myths by Daniel Clauw
Small fiber neuropathy - misnomer, non-specific, not worth getting a skin biopsy
Fibromyalgia is not autoimmune - it is nociplastic pain and treated differently
#ACR24 Review Course
@RheumNow https://t.co/JLyfnfMBML


Antoni Chan MD (Prof) synovialjoints
10 months ago
Pathophysiology of calcinosis. Antonia Valenzuela at Review Course @RheumNow #ACR24 https://t.co/gSJSa2lGXw


TheDaoIndex KDAO2011
10 months ago
Risk factors and crystal composition of in calcinosis. In SSc - calcinosis is assc with vasculopathy, dz duration #ACR24 #ACRReview https://t.co/LJvrdVG1jg
